

Half-Year Results Investor Briefing

Sydney, Australia, Friday, 16 August 2019: Australian medical technology company, Next Science Limited (ASX:NXS) (**Next Science**), advises that it intends to release its results for the half-year ended 30 June 2019 on Friday, 23 August 2019.

Next Science's Managing Director, Judith Mitchell, will host an investor conference call and webcast at **2.00pm** (AEST) on **23 August 2019** to discuss the results. The briefing is expected to last approximately 45 minutes inclusive of question time.

To pre-register for the call, please use the following link:

<https://s1.c-conf.com/diamondpass/nextsciencelimited-10001755-invite.html>

To register to participate via webcast, please use the following link:

<https://webcast.openbriefing.com/5492/>

- - - END - - -

For further information, please contact:

Investor inquiries

Judith Mitchell, Managing Director

Phone: +61 2 9375 7989

Email: investorqueries@nextscience.com

About Next Science

Next Science is a medical technology company headquartered in Sydney, Australia, with a research and development centre in Florida, USA. Established in 2012, the Company's primary focus is on the development and continued commercialisation of its proprietary Xbio technology to reduce the impact of biofilm based infections in human health. Xbio is a unique, non-toxic technology with proven efficacy in eradicating both biofilm based and free-floating bacteria. Next Science owns 100% of the patent protected intellectual property relating to its Xbio technology.

For further information visit: www.nextscience.com.